Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PSEUDO-12 vs ADVIL ALLERGY SINUS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Decongestant; acts on alpha-adrenergic receptors in the nasal mucosa to produce vasoconstriction, reducing edema and nasal congestion.
Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction of nasal mucosa and sinus vessels. Chlorpheniramine is an alkylamine antihistamine that competitively antagonizes histamine H1 receptors, reducing allergic symptoms. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, decreasing prostaglandin synthesis and reducing pain, fever, and inflammation.
FDA: Temporary relief of nasal congestion due to colds, allergies, or sinusitis,Off-label: Adjunct in otitis media, eustachian tube dysfunction
Temporary relief of nasal congestion, sinus pressure, sneezing, runny nose, itchy/watery eyes, and headache due to colds or allergies,Fever reduction,Minor aches and pains
60 mg orally every 4 to 6 hours as needed; maximum 240 mg per day.
1-2 tablets (each tablet contains ibuprofen 200 mg and pseudoephedrine HCl 30 mg) orally every 4-6 hours as needed; maximum 6 tablets per day.
Terminal elimination half-life: 4-6 hours (adults); 6-8 hours (children); prolonged in renal impairment (up to 20 hours in severe disease).
2–4 hours (pseudoephedrine: 5–8 hours); clinical context: requires q4-6h dosing for pain/fever, q6-8h for congestion
Hepatic metabolism via N-demethylation (CYP3A4) and glucuronidation; minor renal excretion as unchanged drug.
Ibuprofen: Primarily hepatic via CYP2C9; Pseudoephedrine: Hepatic via N-demethylation and oxidative metabolism; Chlorpheniramine: Hepatic via CYP2D6 and CYP3A4.
Renal: 70-90% as unchanged drug; biliary/fecal: <10%
Renal (90% as conjugates and metabolites; <10% unchanged); biliary/fecal (<5%)
Binding: 30-40%; primarily to albumin.
Ibuprofen: >99% (albumin); pseudoephedrine: <20% (albumin)
Vd: 2.6-3.5 L/kg; indicates extensive tissue distribution (e.g., lungs, liver, kidney).
Ibuprofen: 0.1–0.2 L/kg; pseudoephedrine: 2.5–3.5 L/kg (extensive tissue distribution)
Oral: 90-100% (immediate-release); 80-90% (extended-release).
Ibuprofen: 80–100% oral; pseudoephedrine: >90% oral
e GFR 30-50 m L/min: 30 mg every 6 hours as needed; maximum 120 mg/day. e GFR <30 m L/min: 30 mg every 12 hours as needed; maximum 60 mg/day.
If GFR <30 m L/min: avoid use of ibuprofen component; pseudoephedrine dose interval may need to be increased (every 8-12 hours) due to reduced clearance.
Child-Pugh A: no adjustment. Child-Pugh B: 30 mg every 6 hours as needed; maximum 120 mg/day. Child-Pugh C: use is not recommended.
Child-Pugh Class A: no adjustment; Class B: use with caution, maximum ibuprofen dose 1200 mg/day; Class C: contraindicated due to risk of hepatotoxicity and renal impairment.
Children 6-12 years: 30 mg orally every 4-6 hours; maximum 120 mg/day. Children 12-17 years: same as adult dosing.
Not recommended for children under 12 years of age; for children ≥12 years: same as adult dose (200 mg ibuprofen/30 mg pseudoephedrine) every 4-6 hours, maximum 6 tablets per day.
Initiate at 30 mg every 6 hours as needed; maximum 120 mg/day due to increased sensitivity and higher risk of adverse effects.
Initiate at lowest effective dose (1 tablet every 6-8 hours); monitor renal function and blood pressure due to increased risk of GI bleeding, cardiovascular events, and pseudoephedrine-induced hypertension.
None.
No FDA black box warning exists for this combination product. However, NSAIDs like ibuprofen carry a black box warning for increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal, especially with prolonged use or in patients with cardiovascular risk factors.
Cardiovascular effects: hypertension, palpitations, arrhythmias; CNS stimulation: insomnia, anxiety, tremor; exacerbation of glaucoma, hyperthyroidism, diabetes; urinary retention in prostatic hypertrophy; rebound congestion with prolonged use.
Cardiovascular risk: NSAIDs increase risk of serious cardiovascular events. Gastrointestinal risk: NSAIDs can cause bleeding, ulceration, and perforation. Hypertension: Pseudoephedrine may elevate blood pressure. Avoid use with MAOIs or within 14 days of stopping. Caution in hyperthyroidism, diabetes, glaucoma, prostatic hypertrophy, and renal impairment.
Severe hypertension, coronary artery disease, concurrent MAO inhibitor therapy, narrow-angle glaucoma, urinary retention, hypersensitivity to sympathomimetics.
Hypersensitivity to any component; Concurrent MAOI therapy; Severe hypertension or coronary artery disease; Active peptic ulcer disease; History of aspirin/NSAID-induced asthma; Pregnancy (especially third trimester); Children under 12 years (per product labeling).
Avoid high-tyramine foods (e.g., aged cheeses, cured meats, fermented products) if taking MAOIs concurrently. Limit caffeine-containing beverages as they may increase CNS stimulation.
Avoid alcohol due to increased risk of GI bleeding and liver toxicity. No known food interactions with chlorpheniramine or pseudoephedrine. Taking with food may reduce gastric irritation from ibuprofen.
FDA Pregnancy Category C. First trimester: no evidence of structural teratogenicity in human studies but avoid due to potential vasoconstriction. Second/third trimester: risk of fetal tachycardia, decreased placental perfusion, and potential for maternal hypertension; prolonged use may cause fetal hypoxia.
First trimester: NSAIDs are associated with increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Third trimester: Risk of premature closure of ductus arteriosus, oligohydramnios, and necrotizing enterocolitis. Avoid use after 30 weeks gestation.
Excreted into breast milk in low amounts (M/P ratio ~0.5). Considered safe at recommended doses; however, monitor infant for irritability or insomnia.
Ibuprofen and pseudoephedrine are excreted into breast milk. Ibuprofen has low milk/plasma ratio (0.01-0.07) and is generally considered compatible. Pseudoephedrine may reduce milk production and cause irritability in infants. Use with caution, especially in preterm infants.
No specific dose adjustment required; however, use lowest effective dose for shortest duration due to physiologic changes (increased renal clearance may slightly reduce plasma levels).
No specific dose adjustments recommended for pregnancy; however, use the lowest effective dose for the shortest duration. Avoid in third trimester. Pseudoephedrine dose remains standard; caution in hypertensive disorders.
Pseudoephedrine is a sympathomimetic amine used as a decongestant. It is contraindicated in severe hypertension, coronary artery disease, and concurrent MAOI use. Monitor for CNS stimulation, insomnia, and elevated blood pressure. Extended-release formulations should not be crushed or chewed.
Advil Allergy Sinus contains ibuprofen (NSAID), chlorpheniramine (first-generation antihistamine), and pseudoephedrine (decongestant). Avoid in patients with aspirin/NSAID allergy, severe hypertension, coronary artery disease, or MAOI use. Caution in elderly due to anticholinergic effects. Pseudoephedrine may cause insomnia and anxiety; avoid evening dosing.
Do not use if you have high blood pressure or heart disease unless directed by a doctor.,Avoid taking within 4 hours of bedtime to prevent insomnia.,Do not crush or chew extended-release tablets.,Limit caffeine intake while taking this medication.,Stop use and consult a doctor if symptoms persist after 7 days.
Do not take if allergic to aspirin or NSAIDs.,Avoid alcohol to reduce risk of stomach bleeding.,Do not use with other products containing NSAIDs or decongestants.,May cause drowsiness; avoid driving or operating machinery.,Do not take for more than 10 days for pain or 3 days for fever.,Consult a doctor if you have high blood pressure, heart disease, glaucoma, or an enlarged prostate.,Pseudoephedrine may cause difficulty sleeping; take last dose at least 4-6 hours before bedtime.,Take with food or milk to minimize stomach upset.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PSEUDO-12 vs ADVIL ALLERGY SINUS, answered by our medical review team.
PSEUDO-12 is a Decongestant that works by Decongestant; acts on alpha-adrenergic receptors in the nasal mucosa to produce vasoconstriction, reducing edema and nasal congestion.. ADVIL ALLERGY SINUS is a NSAID/Decongestant/Antihistamine Combination that works by Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction of nasal mucosa and sinus vessels. Chlorpheniramine is an alkylamine antihistamine that competitively antagonizes histamine H1 receptors, reducing allergic symptoms. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, decreasing prostaglandin synthesis and reducing pain, fever, and inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PSEUDO-12 and ADVIL ALLERGY SINUS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PSEUDO-12 is: 60 mg orally every 4 to 6 hours as needed; maximum 240 mg per day.. The standard adult dose of ADVIL ALLERGY SINUS is: 1-2 tablets (each tablet contains ibuprofen 200 mg and pseudoephedrine HCl 30 mg) orally every 4-6 hours as needed; maximum 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PSEUDO-12 and ADVIL ALLERGY SINUS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PSEUDO-12 is classified as Category C. FDA Pregnancy Category C. First trimester: no evidence of structural teratogenicity in human studies but avoid due to potential vasoconstriction. Second/third trimester: risk of fe. ADVIL ALLERGY SINUS is classified as Category C. First trimester: NSAIDs are associated with increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Third trimester: Risk of premature closure . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.